Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ZK 219477 as second-line therapy in advanced NSCLC
2005-000586-19Phase 2Terminated
- Sponsor
- Bayer
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sagopilone in non-small cell lung cancer (NSCLC), sponsored by Bayer. Primary endpoint: Objective response rate (CR or PR). Started Dec 2005; status: terminated.
02
Drugs
sagopilone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-000586-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000586-19.